To print: Select File and then Print from your browser's menu

Title: Aripiprazole Efficacious for Acute Mania in Relapsing Bipolar 1 Patients: Presented at ECNP

"Aripiprazole Efficacious for Acute Mania in Relapsing Bipolar 1 Patients: Presented at ECNP"

By Bruce Sylvester Special to DG News BARCELONA, SPAIN -- October 9, 2002 -- Aripiprazole appears to be effective and well tolerated in the treatment of acute mania in patients with bipolar disorder. The finding was reported here October 8 at the 15th Congress of the European College of Neuropsychopharmacology (ECNP). "These results suggest that aripiprazole has efficacy, is safe and is well tolerated by relapsing patients with bipolar 1 [mania] who also have acute mania or mixed episode symptoms," said lead investigator Ronald Marcus, MD, clinical investigator at Bristol-Myers Squibb, in Wallingford, United States. "We saw an excellent response to aripiprazole compared to placebo among these patients." The researchers enrolled 262 patients with acute, relapsing bipolar 1 mania for this phase III, multicentre, double-blind, placebo-controlled study. They randomised the subjects to aripiprazole 30 mg/day or placebo for three weeks, reducing the dose to 15 mg/day if therapeutically necessary. Patients remained hospitalised for a minimum of two weeks. The primary measure of efficacy was change in Young Mania Rating Scale (Y-MRS) total score. The researchers defined "response" as a decrease of 50 percent in Y-MRS total score. At end point, the aripiprazole group showed statistically significant improvements in Y-MRS total score compared to placebo (-8.15 versus -3.35, p=0.01 or less). The aripiprazole group also showed a significantly higher response rate compared to the placebo group (40 percent versus 19 percent, p=0.01 or less). Aripiprazole separated from placebo by day 4 for all efficacy variables. Both treatment groups had the same level of discontinuation of therapy and they had no significant variation in body weight. Aripiprazole is an investigational antipsychotic with a unique mechanism of action through partial agonism at D2 receptors, partial agonism at 5HT1A receptors, and antagonism at 5HT2A receptors. Bristol-Myers Squibb funded the study.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.